Lymphoma Antibody
Lymphoma Antibody
![]() Lymphoma/Leukemia-Spleen Tissue Slide (Lymphoma/Leukemia) |
|||
11-606-4um | ProSci | 4 um | 216.6 EUR |
![]() Anapastic Lymphoma Kinase (ALK) Antibody |
|||
20-abx119392 | Abbexa |
|
|
![]() Anapastic Lymphoma Kinase (ALK) Antibody |
|||
abx122001-100ug | Abbexa | 100 ug | 469.2 EUR |
![]() Anapastic Lymphoma Kinase (ALK) Antibody |
|||
abx122523-100ug | Abbexa | 100 ug | 469.2 EUR |
![]() Anapastic Lymphoma Kinase (ALK) Antibody |
|||
abx122756-100ug | Abbexa | 100 ug | 469.2 EUR |
![]() Anaplastic Lymphoma Kinase (ALK) Antibody |
|||
20-abx128738 | Abbexa |
|
|
![]() Anapastic Lymphoma Kinase (ALK) Antibody |
|||
abx010333-100ug | Abbexa | 100 ug | 526.8 EUR |
![]() Anapastic Lymphoma Kinase (ALK) Antibody |
|||
20-abx012794 | Abbexa |
|
|
![]() Anapastic Lymphoma Kinase (ALK) Antibody |
|||
20-abx012911 | Abbexa |
|
|
![]() Anapastic Lymphoma Kinase (ALK) Antibody |
|||
abx033503-400ul | Abbexa | 400 ul | 627.6 EUR |
![]() Anapastic Lymphoma Kinase (ALK) Antibody |
|||
abx033503-80l | Abbexa | 80 µl | 343.2 EUR |
![]() Anapastic Lymphoma Kinase (ALK) Antibody |
|||
abx224320-100ug | Abbexa | 100 ug | 493.2 EUR |
![]() Anapastic Lymphoma Kinase (ALK) Antibody |
|||
abx224449-100ug | Abbexa | 100 ug | 493.2 EUR |
![]() Anapastic Lymphoma Kinase (Alk) Antibody |
|||
abx431093-200ul | Abbexa | 200 ul | 460.8 EUR |
![]() Anapastic Lymphoma Kinase (ALK) Antibody |
|||
abx412203-50ug | Abbexa | 50 ug | 610.8 EUR |
![]() Anaplastic Lymphoma Kinase Antibody (ALK) |
|||
F50550-0.08ML | NSJ Bioreagents | 0.08 ml | 165 EUR |
![]() Anaplastic lymphoma kinase Antibody (Alk) |
|||
F53252-0.08ML | NSJ Bioreagents | 0.08 ml | 165 EUR |
![]() ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V8780-100UG | NSJ Bioreagents | 100ug | 499 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene,NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
![]() ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V8780-20UG | NSJ Bioreagents | 20ug | 219 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene,NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
![]() ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V8780SAF-100UG | NSJ Bioreagents | 100ug | 499 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene,NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
![]() ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V8812-100UG | NSJ Bioreagents | 100ug | 499 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene,NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
![]() ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V8812-20UG | NSJ Bioreagents | 20ug | 219 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene,NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
![]() ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V8812SAF-100UG | NSJ Bioreagents | 100ug | 499 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene,NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
![]() ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V8859-100UG | NSJ Bioreagents | 100ug | 499 EUR |
Description: Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase of the insulin receptor superfamily. ALK is typically expressed at low levels in regions of the developing central and peripheral nervous system. |
|||
![]() ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V8859-20UG | NSJ Bioreagents | 20ug | 219 EUR |
Description: Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase of the insulin receptor superfamily. ALK is typically expressed at low levels in regions of the developing central and peripheral nervous system. |
|||
![]() ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V8859SAF-100UG | NSJ Bioreagents | 100ug | 499 EUR |
Description: Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase of the insulin receptor superfamily. ALK is typically expressed at low levels in regions of the developing central and peripheral nervous system. |
|||
![]() ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V8896-100UG | NSJ Bioreagents | 100ug | 499 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene,NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
![]() ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V8896-20UG | NSJ Bioreagents | 20ug | 219 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene,NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
![]() ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V8896SAF-100UG | NSJ Bioreagents | 100ug | 499 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene,NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
![]() ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V3817-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene, NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
![]() ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V3817-20UG | NSJ Bioreagents | 20 ug | 219 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene, NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
![]() ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V3817SAF-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene, NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
![]() ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V3818-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
Description: Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK. [UniProt] |
|||
![]() ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V3818-20UG | NSJ Bioreagents | 20 ug | 219 EUR |
Description: Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK. [UniProt] |
|||
![]() ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V3818SAF-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
Description: Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK. [UniProt] |
|||
![]() ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V3998-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
Description: Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK. [UniProt] |
|||
![]() ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V3998-20UG | NSJ Bioreagents | 20 ug | 219 EUR |
Description: Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK. [UniProt] |
|||
![]() ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V3998IHC-7ML | NSJ Bioreagents | 7 ml | 499 EUR |
Description: Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK. [UniProt] |
|||
![]() ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V3998SAF-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
Description: Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK. [UniProt] |
|||
![]() ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V7410-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene, NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
![]() ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V7410-20UG | NSJ Bioreagents | 20 ug | 219 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene, NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
![]() ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V7410IHC-7ML | NSJ Bioreagents | 7 ml | 499 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene, NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
![]() ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V7410SAF-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene, NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
![]() ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V9339-100UG | NSJ Bioreagents | 100ug | 499 EUR |
Description: Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. [UniProt] |
|||
![]() ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V9339-20UG | NSJ Bioreagents | 20ug | 219 EUR |
Description: Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. [UniProt] |
|||
![]() ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V9339SAF-100UG | NSJ Bioreagents | 100ug | 499 EUR |
Description: Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. [UniProt] |
|||
![]() Lymphoma tissue array |
|||
LM482c | TissueArray | each | 270 EUR |
Description: Lymphoma tissue array, containing 10 cases of myeloma and normal lymph node tissue, 48 cases/48 cores, replacing LM482b |
|||
![]() Lymphoma tissue array |
|||
LY201 | TissueArray | each | 168 EUR |
Description: Lymphoma tissue array, 20 cases/ 20 cores |
|||
![]() Lymphoma tissue array |
|||
LY2087a | TissueArray | each | 546 EUR |
Description: Lymphoma tissue array, 208 cases/208 cores, replacing LY2087 |
|||
![]() Lymphoma tissue array |
|||
LY302 | TissueArray | each | 168 EUR |
Description: Lymphoma tissue array, 30 cases/ 30 cores (core size 2.0mm), replacing BS20011c. The previous Item# is BS20011d |
|||
![]() Lymphoma tissue array |
|||
NHL803e | TissueArray | each | 348 EUR |
Description: Lymphoma tissue array, 80 cases/80 cores (core size 1.5mm), replacing NHL803d |
|||
![]() Lymphoma tissue array |
|||
T201b | TissueArray | each | 48 EUR |
Description: Lymphoma tissue array, with normal lymph node tissue, 6 cases/24 cores, replacing T201a |
|||
![]() Lymphoma tissue array |
|||
T201c | TissueArray | each | 48 EUR |
Description: Lymphoma tissue array, with normal lymph node tissue, 6 cases/24 cores, replacing T201a |
|||
![]() B Aggressive Lymphoma Protein (BAL) Antibody |
|||
abx038438-100ug | Abbexa | 100 ug | 469.2 EUR |
![]() T-Cell Leukemia / Lymphoma 1A Antibody |
|||
20-abx116012 | Abbexa |
|
|
![]() Lymphoma,18 cases (2.5mm) |
|||
LYM181 | Pantomics | 1 | 228 EUR |
Description: Lymphoma tissue array, 18 cases of various types of nodal and extranodal lymphomas. IHC data include CD3, CD20, CD15, CD20, bcl2 et al. |
|||
![]() Lymphoma, 40 cases (1.1mm) |
|||
LYM401 | Pantomics | 1 | 193.2 EUR |
Description: Lymphoma array, 39 cases of various types of nodal and extranodal lymphoma, non-overlapping with LYM321, LYM761 and LYM771. IHC data include CD3, CD20, CD15, CD20, bcl2 et al. |
|||
![]() Human Lymphoma Tumor lysate |
|||
HTL-1331 | Alpha Diagnostics | 1 mg | 927.6 EUR |
![]() Lymphoma Membrane Tumor Lysate |
|||
XBL-10741 | ProSci | 0.1 mg | 752.1 EUR |
Description: Human lymphoma tissue membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The human lymphoma tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated lymphoma tissue membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated lymphoma tissue membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal. |
|||
![]() Hodgkin's lymphoma tissue array |
|||
HL801a | TissueArray | each | 306 EUR |
Description: Hodgkin's lymphoma tissue array, 45 cases/80 cores, replaced by HL801b |
|||
![]() Hodgkin's lymphoma tissue array |
|||
HL801b | TissueArray | each | 306 EUR |
Description: Hodgkin's lymphoma tissue array, 45 cases/80 cores, replacing HL801a |
|||
![]() Multiple lymphoma tissue array |
|||
LM241b | TissueArray | each | 66 EUR |
Description: Multiple lymphoma tissue array, 12 cases/24 cores (core size 1.0mm), replacing LM241 |
|||
![]() Lymphoma tumor tissue array |
|||
LY1501 | TissueArray | each | 258 EUR |
Description: Lymphoma tumor tissue array, 75 cases/150 cores |
|||
![]() Lymphoma tumor tissue array |
|||
LY2088a | TissueArray | each | 546 EUR |
Description: Lymphoma tumor tissue array, 208 cases/208 cores replacing LY2088 |
|||
![]() Lymphoma cancer tissue array |
|||
NHL482a | TissueArray | each | 222 EUR |
Description: Lymphoma cancer tissue array, 48 cases/48 cores, replacing NHL482 |
|||
![]() B-Cell Lymphoma/leukemia 11B (BCL11B) Antibody |
|||
20-abx148399 | Abbexa |
|
|
![]() B-Cell CLL/Lymphoma 7B (BCL7B) Antibody |
|||
20-abx148479 | Abbexa |
|
|
![]() B-Cell Leukemia/Lymphoma 2 (BCL2) Antibody |
|||
abx148562-100ug | Abbexa | 100 ug | 526.8 EUR |
![]() B-Cell CLL/Lymphoma 11A (Bcl11A) Antibody |
|||
20-abx171391 | Abbexa |
|
|
![]() B-Cell Leukemia/Lymphoma 2 (Bcl2) Antibody |
|||
20-abx171393 | Abbexa |
|
|
![]() B-Cell Leukemia/Lymphoma 2 (Bcl2) Antibody |
|||
20-abx171394 | Abbexa |
|
|
![]() B-Cell Leukemia/Lymphoma 2 (Bcl2) Antibody |
|||
20-abx171395 | Abbexa |
|
|